Key facts
- It has raised $27.5M across 1 recorded rounds; the latest was Seed Round ($3.9M) in Mar 2022.
- Notable investors include Creative Destruction Lab, Keiretsu Forum, Morningside Group, 7G Bioventures, Beresford Ventures — 19 tracked in total.
- Mesentech has filed 1 Form D with the SEC, most recently Apr 2022 ($3.9M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Mesentech
Funding rounds
1 roundsAbout Mesentech
Developer of prostaglandin prodrugs designed to support musculoskeletal regeneration. The company's drug conjugates target mesenchymal stem cells with a potent sub-nano-molar prostaglandin mimetic that is released selectively in the bone, resulting in bone regeneration, enabling hospitals to treat low-bone-density disorders and hopes to rescue non-unions from surgical revision and accelerate bone healing.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2018
- Employees
- 11
- Website
- mesentech.com/
- Ownership
- Privately Held (backing)
Mesentech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mesentech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mesentech in its N-PORT filings yet. We sweep new filings monthly.